生物學的安全性實驗的全球市場:成長，趨勢，及預測(2019年～2024年)

全球生物學的安全性測試市場，在2019年～2024年間預測將以12.4％的年複合成長率成長。而促進市場成長的要素，是醫藥品及生物科技產業的成長，由於高的疾病負擔造成投資的增加，新的生技藥品的生產的增加等。

本報告提供全球生物學的安全性測試市場的相關調查，市場機會和趨勢，成長及阻礙因素，各產品、用途、檢驗、地區的市場分析，競爭情形，主要企業的簡介等資訊。

目錄

第1章 簡介

• 調查成果
• 調查的假設
• 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

• 市場概況
• 成長要素
• 阻礙因素
• 波特的五力分析
  • 新加入廠商的威脅
  • 買主/消費者談判力
  • 供應商談判力
  • 替代產品的威脅
  • 產業內的競爭

第5章 市場區隔

• 各產品
  • 試劑、套件
  • 設備
  • 其他
• 各用途
  • 疫苗、治療藥
  • 細胞、基因治療
  • 血液、血液為基礎的治療
  • 其他
• 各檢查
  • 無菌實驗
  • 細胞株認證及特性評估實驗
  • 微生物附著量實驗
  • 內毒素檢驗
  • 外來性因素檢測檢驗
  • 其他
• 各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲地區
  • 南美

第6章 競爭情形

• 企業簡介
  • Avance Biosciences
  • Cytovance Biologics
  • Eurofins Scientific
  • Lonza
  • Merck KGaA
  • Promega Corporation
  • Thermo Fisher Scientific
  • Toxikon
  • WuXi AppTec

第7章 市場機會及未來趨勢

The biological safety testing market is expected to witness a CAGR of 12.4% during the forecast period.

With the emergence of COVID-19, many pharmaceutical and biotechnology companies began developing novel treatments and vaccines against COVID-19. These rising R&D activities impacted positively the biological safety testing market studied. For instance, in March 2020, Regeneron and Sanofi initiated the development of their biologic Kevzara for the treatment of patients with COVID-19. Kevzara (Sarilumab), jointly developed by Regeneron and Sanofi, also inhibits the IL-6 pathway. Biological safety testing plays a major role in ensuring the purity of vaccines and other biological products. Thus, with the development of new treatments for COVID-19, the demand for biological safety testing has also increased.

Some of the major factors that are driving the market growth are rapidly growing pharmaceutical and biotechnology industries, along with increasing investments, and rising production of new biologics due to the high disease burden. For instance, in 2021, biologics accounted for second of the top-eight drugs in terms of revenue. Humira (adalimumab), which was developed by AbbVie for the treatment of rheumatoid arthritis, psoriasis, Crohn's, and other autoimmune diseases, led to USD 20.7 billion sales, as per the Top 15 Best-selling Drugs of 2021 report. Humira was also the fastest-growing biological drug.

Further, biotechnology-derived products or biologicals have effectively made their way into various aspects of healthcare, including diagnoses, prevention, and treatments of diseases. However, there remain certain potential safety concerns, which generally arise from the manufacturing processes and complex biological and structural characteristics of these products. Therefore, these products need detailed and systematic biological safety testing, that eventually enables the adequate assessment of safety, before any kind of clinical investigation. Hence, the market is expected to thrive over the forecast period.

However, the biological safety process is quite time-consuming and complex which is expected to hinder the market growth.

Key Market Trends

Bioburden Testing Segment is Expected to Hold Significant Share in the Test Segment of the Market Over the Forecast Period

Bioburden Testing Segment is expected to hold a significant share in the test segment of the market over the forecast period. Organizations like the World Health Organization have also released instructions for health managers and health workers on required infrastructures and standard procedures for effective sterilization, and decontamination of medical devices. These factors are expected to increase the demand for proper sterilization, which is expected to boost the demand for Bioburden testing as it acts as an efficient tool in the validation of validation and revalidation of sterilization processes, assessment of the efficiency of cleaning processes, routine monitoring of manufacturing processes to ensure safety.

Bioburden testing is an integral part of validation and revalidation of sterilization processes, assessment of the efficiency of cleaning processes, routine monitoring of manufacturing processes, monitoring of raw materials, components, or packaging, and overall environmental monitoring programs. The high adoption rate determines bioburden limits in wide-ranging biologics and medical devices. Further, the development of new products in the market is expected to accelerate the market studied. For instance, in December 2019, the company launched the BD Kiestra IdentifA system in Europe and Canada, which is used for microbial identification. It has incorporated automated sample processing steps that ensure accuracy and minimal error.

Furthermore, there are high bioburden and microbial contamination rates during pharmaceutical and biologics manufacturing, which is expected to drive government and private organizations to improve underlying biological safety practices. Hence, all these practices performed might drive the overall market.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America Dominates the Market and is expected to do the same in the forecast period. The United States is expected to contribute majorly to the market growth of this region. Due to the outbreak of COVID-19, the rising R&D activities related to COVID-19 have impacted the market growth positively.

The growth of the biological safety testing market in this region can be directly attributed to the growing biotechnology and pharmaceutical industries in the region. The high growth of these industries is further attributable to factors, such as innovative technologies and the presence of favorable government initiatives. Also, the emerging need for validation of drugs and devices process of manufacturing is expected to boost the demand for the market studied. According to the United States Food & Drug Administration (FDA) report, in 2021, the United States had about 4,814 manufacturing sites for drugs.

Additionally, the advanced healthcare infrastructure and rising R&D spending are expected to increase the revenue size further. According to the data of Pharmaceutical Research and Manufacturers of America (PhRMA), in the United States, about USD 83 billion were spent by the pharmaceutical industry on the R&D. Thus, this is expected to boost the market growth over the forecast period.

Competitive Landscape

The biological safety testing market is highly competitive and consists of a few major players. Companies, like Avance Biosciences, Cytovance Biologics, Eurofins Scientific, Lonza, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Toxikon, and WuXi AppTec, among others, hold a substantial share in the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growth in the Pharmaceutical and Biotechnology Industries, along with Increasing Investments
  • 4.2.2 Rising Production of New Biologics due to High Disease Burden
• 4.3 Market Restraints
  • 4.3.1 Time Consuming Approval Process
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size - Value in USD million)

• 5.1 By Product
  • 5.1.1 Reagents and Kits
  • 5.1.2 Instruments
  • 5.1.3 Other Products
• 5.2 By Application
  • 5.2.1 Vaccines and Therapeutics
  • 5.2.2 Cellular and Gene Therapy
  • 5.2.3 Blood and Blood-based Therapy
  • 5.2.4 Other Applications
• 5.3 By Test
  • 5.3.1 Sterility Tests
  • 5.3.2 Bioburden Tests
  • 5.3.3 Endotoxin Tests
  • 5.3.4 Other Tests
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Avance Biosciences
  • 6.1.2 Cytovance Biologics
  • 6.1.3 Eurofins Scientific
  • 6.1.4 Lonza
  • 6.1.5 Merck KGaA
  • 6.1.6 Promega Corporation
  • 6.1.7 Thermo Fisher Scientific
  • 6.1.8 Toxikon
  • 6.1.9 WuXi AppTec
  • 6.1.10 Biomerieux SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS